Neurovascular Coupling in Patients With Open Angle Glaucoma
1 other identifier
observational
15
1 country
1
Brief Summary
A variety of studies demonstrate that ocular blood flow is altered in glaucoma. Various animal and human studies have shown an increase in retinal and optic nerve head blood flow in response to diffuse luminance flicker. Based on studies with ERG, this effect has been attributed to augmented activity in the retinal ganglion cells and associated axons indicating a coupling mechanism between neuronal activity and retinal blood flow. Whereas a variety of studies have confirmed these effects, the knowledge about this coupling in the retina of patients with glaucoma is sparse. Recently the investigators could show that flicker induced vasodilatation is blunted in patients with open angle glaucoma. However, the investigators results are limited by the fact that only data about retinal vessel diameters, not blood flow per se, are available. The further development of the investigators current flicker stimulation technique now allows us to determine blood flow velocity during flicker stimulation. Thus, in the current study, the investigators set out to determine whether this blood flow response is impaired in patients with glaucoma as compared to those in healthy volunteers and whether this is related to altered neural activity. The study objective was, to investigate whether the blood flow response to flicker stimulation is altered in patients with glaucoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2006
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2007
CompletedFirst Submitted
Initial submission to the registry
July 2, 2008
CompletedFirst Posted
Study publicly available on registry
December 19, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2012
CompletedNovember 21, 2014
November 1, 2014
6 months
July 2, 2008
November 20, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Retinal blood velocity (laser Doppler velocimetry)
measurements done only once on the studyday
Retinal arterial and venous diameter (Retinal vessel analyzer)
measurements done only once on the studyday
Optic nerve head blood flow (laser Doppler flowmetry)
measurements done only once on the studyday
Latency and amplitude (pattern ERG)
measurements done only once on the studyday
Secondary Outcomes (1)
Mean arterial pressure
measurements done only once on the studyday
Study Arms (2)
a
15 male and 15 female patients with glaucoma
b
30 sex matched healthy volunteers
Interventions
non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
Eligibility Criteria
You may qualify if:
- Men and women aged between 20 and 80 years.
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant.
- Men and women will be included in equal parts. A pregnancy test will be performed at screening.
- Ametropia of less than 3 diopters and anisometropia of less than 1 diopter.
You may not qualify if:
- Treatment with vasoactive drugs.
- Presence of intraocular pathology other than open angle glaucoma.
- Presence of ocular hypertension or PEX (pseudoexfoliation) glaucoma
- History or family history of epilepsy.
- Pregnancy.
- Diabetes mellitus.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Clinical Pharmacology, Meical University of Vienna, Austria
Vienna, 1090, Austria
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gabriele Fuchsjäger Mayrl, MD
Department of Clinical Pharmacology, Meical University of Vienna
Study Design
- Study Type
- observational
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
July 2, 2008
First Posted
December 19, 2008
Study Start
October 1, 2006
Primary Completion
April 1, 2007
Study Completion
May 1, 2012
Last Updated
November 21, 2014
Record last verified: 2014-11